ondansetron has been researched along with Premature Birth in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Premature Birth: CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results do not suggest that ondansetron increases the risk of preterm birth or gestational hypertensive disorders." | 8.02 | Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. ( Boggess, K; Engel, SM; Funk, MJ; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| "Our results do not suggest that ondansetron increases the risk of preterm birth or gestational hypertensive disorders." | 4.02 | Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. ( Boggess, K; Engel, SM; Funk, MJ; Lund, JL; Stürmer, T; Suarez, EA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suarez, EA | 1 |
| Boggess, K | 1 |
| Engel, SM | 1 |
| Stürmer, T | 1 |
| Lund, JL | 1 |
| Funk, MJ | 1 |
1 other study available for ondansetron and Premature Birth
| Article | Year |
|---|---|
Ondansetron use in early pregnancy and the risk of late pregnancy outcomes.
Topics: Antiemetics; Female; Humans; Infant, Newborn; Ondansetron; Pregnancy; Pregnancy Outcome; Premature B | 2021 |